Management of acute myocardial infarction in Auckland

New Zealand Medical Journal

Volumn 109, Issue 1025, 1996, Pages 248-251

  French, John ^b,c   Williams, Barbara ^b   Hart, Hamish ^b   Woo, Kam ^b   Wang, Lexin ^b   Grant, Judith ^b   Ingram, Christine ^b   O'Brien, Pauline ^b   Poole, June ^b   Sharpe, Norman ^a,b   Williams, Miles ^b   White, Harvey ^b  

^a Department of Medicine ^*

^b NORTH SHORE HOSPITAL   (New Zealand)

^c GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; FIBRINOLYTIC AGENT; HEPARIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ASPIRIN; CORONARY CARE UNITS; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEW ZEALAND; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; THROMBOLYTIC THERAPY;

EID: 15844388216     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
2. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy -I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
4. Lau J, Antman EM, Jimenez-Silva J, Kupelnick BA, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-54.
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
6. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
7. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected myocardial infarction. Lancet 1995; 345: 669-85.
8. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Longterm Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.
9. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-7.
10. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891-4.
11. Woods KL, Ketley D. Thrombolysis and acute myocardial infarction. Lancet 1994; 343: 232-3.
12. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E, for the SAVE Investigators. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med 1992; 327: 241-7.
13. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
14. White HD, Charbonnier B, Van de Werf, et al. An aspirin-controlled study of MK-852 in patients with unstable angina [abstract]. Circulation 1993; 86: 1-201.
15. Rustige J, Schiele R, Burczyk U, Koch A, Tebbe U, Senges J, for the ALKK Study Group. High hospital mortality despite frequent use of thrombolysis in acute myocardial infarction [abstract]. Eur Heart J 1995; 16 Suppl: 9.
16. Rogers WJ, Bowlby LJ, Chandra NC, et al for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103-14.
17. Williams B. Admissions to a coronary-care unit over the past seven years (1973-79). NZ Med J 1981; 679: 158-60.
18. Jagger JD, Murray RG, Davies MK, Littler WA, Flint EJ. Eligibility for thrombolytic therapy in acute myocardial infarction. Lancet 1987; 1: 34- 5.
19. Doorey AJ, Michelson EL, Topol EJ. Thrombolytic therapy of acute myocardial infarction: Keeping the unfilled promises. JAMA 1992; 268: 3108-14.
20. Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. Br Med J 1995; 311: 793-6.
21. Doggen CJM, Palen JVD, Beaglehole R. Trends in medical management of acute myocardial infarction, Auckland 1983-90. NZ Med J 1993; 106: 278-81.
22. White HD. Selecting a thrombolytic agent. Cardiology Clinics 1995; 13: 347-54.
23. Barbash GI, White HD, Modan M, Van de Werf F, for the investigators of the international tissue plasminogen activator streptokinase mortality trial. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22: 707-13.
24. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic vitreous hemorrhage. Arch Opthalmol 1987; 105: 191-5.
25. White HD, Yusuf S. Issues regarding the use of heparin following streptokinase therapy. J Thrombosis Thrombolysis 1995; 2: 5-10.
26. Held P, Yusuf S, Furberg C. Effects of calcium antagonists on initial infarction, reinfarction and mortality in acute myocardial infarction and unstable angina. BMJ 1989; 299: 1187-92.
27. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
28. Gordon GD. Digoxin: does it have a place in contemporary practice? Auckland: National Heart Foundation of New Zealand; 1995 Oct Technical Report No.:66.
29. Mark DB, Shaw LK, DeLong ER, Califf RM, Pryor DB. Absence of sex bias in the referral of patients for cardiac catheterization. N Engl J Med 1994; 330: 1101-6.